论文部分内容阅读
目的观察前列腺癌患者血清甲状旁腺相关蛋白（ＰＴＨｒＰ）与病情及前列腺特异抗原（ＰＳＡ）的关系。方法采用免疫放射法（ＩＲＭＡ）和放射免疫法（ＲＩＡ）测定３１例前列腺癌患者血清ＰＴＨｒＰ、ＰＳＡ和钙离子，并以５０例前列腺增生症（ＢＰＨ）、５５例健康人和５７例其它恶性肿瘤患者作对照。结果前列腺癌组血清ＰＴＨｒＰ（４．６±４．４ｐｍｏｌ／Ｌ）和ＰＳＡ（８０．０±５２．６μｇ／Ｌ）明显高于ＢＰＨ和健康组（均为Ｐ＜０．０１）。３１例前列腺癌患者中１３例（４１．６％）血清ＰＴＨｒＰ增高，这１３例均属Ｄ期，其血清ＰＴＨｒＰ水平明显高于Ａ期（Ｐ＜０．０１）。２１例前列腺癌伴发高钙血症（ＨＨＭ）者血清ＰＴＨｒＰ与ＰＳＡ呈正相关关系（ｒ＝０．８２３，Ｐ＜０．００１）。ＢＰＨ组无１例血清ＰＴＨｒＰ增高。结论血清ＰＴＨｒＰ与前列腺癌的病程进展有关，其含量增高表明肿瘤已属晚期
Objective To observe the relationship between the serum parathyroid hormone related protein (PTHrP) and the disease and prostate specific antigen (PSA) in patients with prostate cancer. Methods Serum levels of PTHrP, PSA and calcium in 31 patients with prostate cancer were determined by radioimmunoassay (IRMA) and radioimmunoassay (RIA). Fifty patients with benign prostatic hyperplasia (BPH), 55 healthy individuals and 57 other malignant tumors Patients as a control. Results The serum levels of PTHrP (4.6 ± 4.4pmol / L) and PSA (80.0 ± 52.6μg / L) in prostate cancer group were significantly higher than those in BPH and healthy group (all P <0.01). Thirteen patients (31.6%) had higher serum PTHrP in 31 cases of prostate cancer. All 13 patients were in D stage, and serum PTHrP level was significantly higher than that in A stage (P <0.01). There was a positive correlation between serum PTHrP and PSA in 21 cases of prostate cancer with hypercalcemia (HHM) (r = 0.823, P <0.001). No BPH group serum PTHrP increased. Conclusions Serum PTHrP is associated with the progression of prostate cancer. The higher content of PTHrP indicates that the tumor is late